Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Analysis of the transforming and growth suppressive activities of the PAX3-FKHR oncoprotein

Oncogene volume 23, pages 6864–6871 (2004)Cite this article

Abstract

The 2;13 chromosomal translocation occurs in most cases of the cancer alveolar rhabdomyosarcoma (ARMS), and juxtaposes the genes encoding the PAX3 and FKHR transcription factors. The resulting chimeric protein PAX3-FKHR is a potent transcriptional activator, and is hypothesized to function as a dominant acting oncogene. To investigate its biological function, PAX3-FKHR was transduced into three immortalized murine cell lines in either a constitutive or inducible manner. These cells only tolerate expression of low PAX3-FKHR levels, which is sufficient for transformation in NIH3T3 cells. In contrast, higher PAX3-FKHR levels, which are comparable to the endogenous level expressed in ARMS cells, result in growth suppression. To determine as to which PAX3 functional domains are needed for growth suppression and transformation, inactivating mutations were introduced into the paired box and homeodomain of PAX3-FKHR. In these experiments, the homeodomain is necessary for transformation, but not growth suppression; whereas the paired box is not required for transformation but mediates growth suppression. In summary, our findings demonstrate that the transforming and growth suppressive activities of PAX3-FKHR are dominant at different activity levels and are mediated by distinct functional domains. These findings are consistent with the hypothesis that distinct expression pathways are operative in these opposing phenotypic end points.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Barr FG . (1997). J. Pediatr. Hematol. Oncol., 19, 483–491.

  • Barr FG, Galili N, Holick J, Biegel JA, Rovera G and Emanuel BS . (1993). Nat. Genet., 3, 113–117.

  • Bennicelli JL, Edwards RH and Barr FG . (1996). Proc. Natl. Acad. Sci. USA, 93, 5455–5459.

  • Bernasconi M, Remppis A, Fredericks WJ, Rauscher FJ and Schafer BW . (1996). Proc. Natl. Acad. Sci. USA, 93, 13164–13169.

  • Berner JM, Forus A, Elkahloun A, Meltzer PS, Fodstad O and Myklebost O . (1996). Genes Chromosomes Cancer, 17, 254–259.

  • Bridge JA, Liu J, Qualman SJ, Suijkerbuijk R, Wenger G, Zhang J, Wan X, Baker KS, Sorensen P and Barr FG . (2002). Genes Chromosomes Cancer, 33, 310–321.

  • Bridge JA, Liu J, Weibolt V, Baker KS, Perry D, Kruger R, Qualman S, Barr F, Sorensen P, Triche T and Suijkerbuijk R . (2000). Genes Chromosomes Cancer, 27, 337–344.

  • Burel SA, Harakawa N, Zhou L, Pabst T, Tenen DG and Zhang DE . (2001). Mol. Cell. Biol., 21, 5577–5590.

  • Davis RJ and Barr FG . (1997). Proc. Natl. Acad. Sci. USA, 94, 8047–8051.

  • del Peso L, Gonzalez VM, Hernandez R, Barr FG and Nunez G . (1999). Oncogene, 18, 7328–7333.

  • Deneen B and Denny CT . (2001). Oncogene, 20, 6731–6741.

  • Fortin AS, Underhill DA and Gros P . (1997). Hum. Mol. Genet., 6, 1781–1790.

  • Kappen C, Schughart K and Ruddle FH . (1993). Genomics, 18, 54–70.

  • Lam PY, Sublett JE, Hollenbach AD and Roussel MF . (1999). Mol. Cell. Biol., 19, 594–601.

  • Littlewood TD, Hancock DC, Danielian PS, Parker MG and Evan GI . (1995). Nucleic Acids Res., 23, 1686–1690.

  • Matsuzaki H, Daitoku H, Hatta M, Tanaka K and Fukamizu A . (2003). Proc. Natl. Acad. Sci. USA, 100, 11285–11290.

  • Serrano M, Lin AW, McCurrach ME, Beach D and Lowe SW . (1997). Cell, 88, 593–602.

  • Tsokos M, Webber BL, Parham DM, Wesley RA, Miser A, Miser JS, Etcubanas E, Kinsella T, Grayson J, Glatstein E, Pizzo PA and Triche TJ . (1992). Arch Pathol Lab Med, 116, 847–855.

  • Wilson DS, Guenther B, Desplan C and Kuriyan J . (1995). Cell, 82, 709–719.

  • Xu HE, Rould MA, Xu W, Epstein JA, Maas RL and Pabo CO . (1999). Genes Dev., 13, 1263–1275.

Download references

Acknowledgements

This work was supported by Grants CA64202 and CA71838 (to FGB) from the National Cancer Institute.

Author information

Authors and Affiliations

  1. Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

    Shujuan J Xia & Frederic G Barr

Authors
  1. Shujuan J Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frederic G Barr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frederic G Barr.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xia, S., Barr, F. Analysis of the transforming and growth suppressive activities of the PAX3-FKHR oncoprotein. Oncogene 23, 6864–6871 (2004). https://doi.org/10.1038/sj.onc.1207850

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207850

Keywords

This article is cited by

Search

Advanced search

Quick links